Science Daily: Pharmacology News

NOVEMBER 27, 2024

A tiny, four-fingered 'hand' folded from a single piece of DNA can pick up the virus that causes COVID-19 for highly sensitive rapid detection and can even block viral particles from entering cells to infect them, researchers report. Dubbed the NanoGripper, the nanorobotic hand also could be programmed to interact with other viruses or to recognize cell surface markers for targeted drug delivery, such as for cancer treatment.

DNA

FDA Law Blog: Drug Discovery

NOVEMBER 10, 2024

By Sarah Wicks & James E. Valentine — The U.S. Food and Drug Administration (FDA) plays a pivotal role in fostering the development of treatments for rare diseases through its Orphan Products Grants Program. Each year, FDA selects a limited number of clinical trials to fund to help sponsors pursue development of medical products for rare diseases and advance their field.

Clinical Development

Covalent Modifiers

NOVEMBER 15, 2024

Fereshte Ghorbani, Shaochen You, Gennadii A. Grabovyi, Mannkyu Hong, Garrett Lindsey, Arnab K. Chatterjee, and Michael J. Bollong Journal of the American Chemical Society 2024 DOI: 10.1021/jacs.4c05711 Cysteine reactive groups are a mainstay in the design of covalent drugs and probe molecules, yet only a handful of electrophiles are routinely used to target this amino acid.

Small Molecule

Perficient: Drug Development

NOVEMBER 20, 2024

Introduction to Multiclass Text Classification with LLMs Multiclass text classification (MTC) is a natural language processing (NLP) task where text is categorized into multiple predefined categories or classes. Traditional approaches rely on training machine learning models, requiring labeled data and iterative fine-tuning. However, with the advent of large language models (LLMs), this task can now be approached differently.

Engineering

Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health

AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!

Clinical Trials

Broad Institute

NOVEMBER 4, 2024

A transatlantic collaboration is uncovering the role of key genetic variants in common diseases like type 2 diabetes and obesity By Corie Lok November 4, 2024 Breadcrumb Home A transatlantic collaboration is uncovering the role of key genetic variants in common diseases like type 2 diabetes and obesity The Novo Nordisk Foundation Center for Genomic Mechanisms of Disease brings together Danish and Broad scientists.

Disease

Drug Target Review

NOVEMBER 25, 2024

In the world of biopharmaceuticals, Dr Catherine Pickering stands out as a pioneering leader. As the CEO of iOnctura, an innovative oncology biopharmaceutical company she co-founded in 2017, Catherine has played a key role in advancing the development of highly targeted small molecules aimed at revolutionising cancer treatment. Her journey in drug R&D and business development has been marked by significant achievements, including leading groundbreaking efforts to treat neglected cancers and

Treatment

The Premier Consulting Blog

NOVEMBER 6, 2024

Inhaled combination products (ICP) have emerged as a significant advancement in the treatment of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and other pulmonary conditions. Inhalation offers a targeted route of drug delivery directly to the lungs, minimizing systemic side effects and maximizing therapeutic benefits.

Production

Common Sense for Drug Policy Blog

NOVEMBER 26, 2024

"Pink Cocaine", Otherwise Known As Tusi "The tusi phenomenon complicates the drug landscape because it has the potential to confuse both people who use and researchers alike. With respect to people who use, given the drug concoction’s name, people may assume the drug is 2C/2C-B. Since many partiers are unfamiliar with 2C series drugs ( 14 ), there is also potential for people to simply think this is a new (and perhaps benign) drug – especially given that the powder is pink with a sweet scent.

Production

Perficient: Drug Development

NOVEMBER 20, 2024

Quantum computing is rapidly transitioning from theory to reality, using the principles of quantum mechanics to achieve computational power far beyond traditional computers. Imagine upgrading from a bicycle to a spaceship—quantum computers can solve complex problems at extraordinary speeds. However, this leap in computing power poses significant challenges, particularly for cybersecurity, which forms the backbone of data protection in our digital world.

Government

Covalent Modifiers

NOVEMBER 7, 2024

Thomas M. Geiger, Radosław P. Nowak Annual Reports in Medicinal Chemistry , 2024 [link] Proteolysis targeting chimeras (PROTACs) are hetero-bifunctional molecules that remove disease-causing proteins through the means of targeted protein degradation (TPD). Since their proof-of-concept over 20 years ago, PROTACs emerged as new modality in drug discovery and chemical biology.

Targeted Protein Degradation

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Treatment

Drug Target Review

NOVEMBER 11, 2024

Immunotherapy has emerged as a powerful tool in our fight against cancer. By mobilising the body’s immune system, this approach offers new hope for patients. However, despite impressive advancements, many patients still do not respond to current immunotherapy treatments. This is partly because cancer cells are shrewd and often develop ways to evade immune detection.

Immune Response

Broad Institute

NOVEMBER 25, 2024

Ladders to Cures (L2C) Accelerator By Maria Nemchuk November 25, 2024 Breadcrumb Home Ladders to Cures (L2C) Accelerator The Ladders to Cures (L2C) Accelerator aims to catalyze progress across the research ecosystem and accelerates advances leading to treatments and cures for patients with rare genetic diseases. We are a community of scientists, physicians, patient advocacy groups, AI/machine learning experts and biopharma veterans working together to gain new mechanistic insights and advance tr

Clinical Trials

Alta Sciences

NOVEMBER 15, 2024

4 Essential Topics to Cover in Your First CRO Meeting pmjackson Fri, 11/15/2024 - 19:22 Starting a partnership with a contract research organization (CRO) is a sometimes intimidating—yet exciting—first step in your drug development journey. Whether you’re at the discovery phase or gearing up for a clinical trial , your first conversation with a CRO is an excellent opportunity to assess the cultural fit and collaborative potential. 4 Talking Points to Expect in Your First CRO Meeting To help you

Drug Development

Chemical Biology and Drug Design

NOVEMBER 13, 2024

A series of chromone derivatives were designed and synthesized. We established a NOX4 overexpression model using the NRK-49F and identified compound 14m as highly active through the assessment of intracellular ROS levels. This investigation positions 14m as a noteworthy NOX4 inhibitor, shedding light on its regulatory role in renal fibroblasts. ABSTRACT Nicotinamide adenine dinucleotide phosphate oxidase 4 (NOX4) has emerged as a promising target for developing drugs to tackle renal fibrosis.

Regulations

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Clinical Trials

PPD

NOVEMBER 11, 2024

It is hard to ignore some of the most pressing, long-term trends driving the push to accelerate innovation and progress in drug development. From an aging population increasing health care demand to urgent, unmet medical needs, there are clear drivers to advance safe and effective medicines to patients faster than ever. According to the United Nation’s 2024 World Population Prospects data, the global population of those 65 years old and over will grow from 0.8 billion in 2023 to 1.2 billion in 2

Drug Development

Covalent Modifiers

NOVEMBER 2, 2024

W Liu, R Patouret, E Peev, S Barluenga, N Winssinger Helvetica Chimica Acta , 2024 [link] Herein, we detail an extension of our research on the synthesis of a small library of furanoheliangolides and the characterization of the covalent interaction between goyazensolide and IPO5. Using a build‐couple‐pair strategy, we assembled a small library of germacrene‐type lactones and diversified them into eight groups of structurally different analogues.

Research

Codon

NOVEMBER 3, 2024

This essay by Kamal Nahas concludes Issue 04 of Asimov Press. In the 1924 novel, The Magic Mountain , Thomas Mann describes a sanatorium patient named Anton Ferge as he undergoes a painful tuberculosis (TB) treatment. “I lie there with my face covered, so I can’t see anything,” Anton says. “I feel myself being pinched and squeezed, that is the flesh they are laying back and pegging down.” Ferge’s harrowing treatment is a lung-flattening artificial pneumothorax

Vaccine

Fierce BioTech

NOVEMBER 22, 2024

AI in Pharma: Benefits, Risks and the Road Ahead AI is revolutionizing the drug development process, streamlining and accelerating every stage, from research to approval and marketing. This whitepaper explores the benefits and risks of AI in the pharmaceutical industry and examines its future. jkarimi Fri, 11/22/2024 - 15:01 AI is revolutionizing the drug development process, streamlining and accelerating every stage, from research to approval and marketing.

Drug Development

Advertisement

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

Clinical Trials

Broad Institute

NOVEMBER 21, 2024

Researchers identify source of a brain cancer’s deadly transformation By Corie Lok November 21, 2024 Breadcrumb Home Researchers identify source of a brain cancer’s deadly transformation Slow-growing glioma tumors become more aggressive when their cells shift identities and acquire new genetic mutations. By Wynne Parry November 21, 2024 Credit: Castro Lab, Michigan Medicine, Ann Arbor Glioma tumor cells seen under a microscope Related news Targeted drug treatment leads tumor cells to imitate vir

Research

Chemical Biology and Drug Design

NOVEMBER 4, 2024

Alzheimer's disease (AD) is a progressive age-related neurodegenerative brain disorder that destroys memory and other important mental functions. This review article comprehensively summarized the recent advancements in galantamine and its hybrid analogs as potential therapeutic agents for the management of AD. Furthermore, we also provided the design, synthesis, and SAR analysis of the galantamine-based compounds used in the last decades for the management of AD.

Disease

Nvidia Developer: Drug Discovery

NOVEMBER 13, 2024

The ability to compare the sequences of multiple related proteins is a foundational task for many life science researchers. This is often done in the form of a. The ability to compare the sequences of multiple related proteins is a foundational task for many life science researchers. This is often done in the form of a multiple sequence alignment (MSA), and the evolutionary information retrieved from these alignments can yield insights into protein structure, function, and evolutionary history.

Science

Covalent Modifiers

NOVEMBER 15, 2024

Sijie Wang, Emily C. Woods, Jeyun Jo, Jiyun Zhu, Althea Hansel-Harris, Matthew Holcomb, Nichole J. Pedowitz, Tulsi Upadhyay, John Bennett, Matthias Fellner, Ki Wan Park, Anna Zhang, Tulio A. Valdez, Stefano Forli, Alix I Chan, Christian N. Cunningham, Matthew Bogyo bioRxiv 2024.11.06.622387; doi: [link] Staphylococcus aureus (S. aureus) is an opportunistic human pathogen that causes over one million deaths around the world each year.

Advertisement

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

Clinical Trials

Drug Target Review

NOVEMBER 28, 2024

As the journey toward realising the full potential of precision medicine continues, one question frequently arises among pharma executives and biotech founders: why is progress so slow? A significant part of the answer may lie in the limitations of current technology in handling complex, multi-modal data – data that is crucial for advancing drug discovery and identifying new targets.

Science

Zobio

NOVEMBER 21, 2024

Molecular glues have emerged as an exciting new class of agents in drug discovery, offering a novel mechanism to modulate protein function, both as protein degraders and for other therapeutic targets. Unlike traditional drugs that inhibit or block protein activity, molecular glues enhance or induce new protein-protein interactions (PPIs), allowing them to activate biological pathways rather than suppressing them.

Drugs

Alta Sciences

NOVEMBER 13, 2024

Altasciences’ Commitment to Supporting Pharma and Biotech With Comprehensive Bioanalytical Services pmjackson Wed, 11/13/2024 - 14:50 Greater Montréal, Québec, 11/13, 2024 — Altasciences , a trusted drug development research partner for over 30 years, continues its commitment to providing world-class bioanalytical services. This core business supports both preclinical and clinical studies conducted at Altasciences’ facilities, while also offering an extensive standalone solution to meet the div

Clinical Pharmacology

Common Sense for Drug Policy Blog

NOVEMBER 15, 2024

Misrepresentation of Drugs in the Unregulated Market "The misrepresentation of illicit drugs is a persistent problem in unregulated markets ( Barratt et al., 2024 , Marshman and Gibbins, 1969 ). Misrepresentation can take several forms, including dilution of alleged drugs with inactive fillers, adulteration with other active drugs or contaminants, and substitution with other substances.

Marketing

Perficient: Drug Development

NOVEMBER 14, 2024

How to ensure your toolset matches your vision, team and long term goals. Seems common sense right? Use the right tool for the right purpose. However, in the DXP and Drupal space, we often see folks trying to fit their project to the tool and not the tool to the project. There are many modules, profiles, and approaches to building Drupal out there, and most all of them have their time and place.

International

Covalent Modifiers

NOVEMBER 8, 2024

Mengzhen Gu, Xiaoqing Xu, Xiaoping Wang, Yun Wang, Yu Zhao, Xiaoxian Hu, Lu Zhu, Zhenzhong Deng, and Chao Han Journal of Medicinal Chemistry 2024 DOI: 10.1021/acs.jmedchem.4c02277 Histone lysine-specific demethylase 1 (LSD1) is hyperactive in breast cancer, which is associated with the metastasis of the tumor. Current irreversible LSD1 inhibitors are all synthesized by covalently binding to the flavin adenine dinucleotide cofactor, which often have side effects due to the high affinity for a var

Treatment

Codon

NOVEMBER 1, 2024

Dario Amodei, the CEO of Anthropic , recently published an essay called “ Machines of Loving Grace.” It sketches out his vision for how AI could radically transform neuroscience, economics, diplomacy, and the meaning of work. Amodei also imagines the ways AI could accelerate biological research and yield miraculous cures in the 21st century; everything from the prevention and treatment of nearly all infectious and inherited diseases to the elimination of most cancers. “Biology

DNA

National Institute on Drug Abuse: Nora's Blog

NOVEMBER 25, 2024

Syringe services for people who inject drugs are enormously effective, but remain underused area Mon, 11/25/2024 - 10:38 Nora's Blog November 25, 2024 Image NIDA Image Nearly 30 years of research show that providing testing, counseling, and sterile injection supplies to people who inject opioids and other drugs helps prevent transmission of infectious diseases, without increasing drug-related or other crimes in the vicinity.

Drugs

Alta Sciences

NOVEMBER 4, 2024

Case Study: How to Ensure Safety While Manufacturing Highly Potent APIs aasimakopoulos Mon, 11/04/2024 - 17:37 Highly potent active pharmaceutical ingredients (API) require careful attention to safety and handling during formulation and manufacturing. This blog explores the process required for manufacturing a highly potent API for an ophthalmic indication, based on a case study involving loteprednol etabonate, a topical corticosteroid used to treat eye inflammations.

Engineering

Nvidia Developer: Drug Discovery

NOVEMBER 18, 2024

AI models for science are often trained to make predictions about the workings of nature, such as predicting the structure of a biomolecule or the properties of. AI models for science are often trained to make predictions about the workings of nature, such as predicting the structure of a biomolecule or the properties of a new solid that can become the next battery material.

Science